The Best of WCLC 2025 San Francisco – Northern California is a regional educational initiative developed by the International Association for the Study of Lung Cancer (IASLC) to deliver key highlights and practice-changing data from the World Conference on Lung Cancer (WCLC) to healthcare professionals who were unable to attend the international event. This one-day, multi-disciplinary CE activity is designed to distill the most impactful advances across thoracic oncology into an accessible and clinically relevant format.
Led by a panel of national and local faculty, the agenda features concise presentations on critical updates in screening, diagnosis, staging, surgery, radiation therapy, systemic treatments (including chemotherapy, targeted therapy, and immunotherapy), and late-breaking clinical trial data. Each session is followed by interactive panel discussions to encourage real-time clinical dialogue and peer exchange. The activity is structured to improve clinical competence, support practice-based decision-making, and ultimately enhance patient care outcomes for individuals with lung cancer and other thoracic malignancies.
This educational activity is intended for physicians, advanced practice providers (nurse practitioners, physician associates), and other healthcare professionals involved in the care of patients with thoracic malignancies, including but not limited to medical oncologists, surgical oncologists, radiation oncologists, pulmonologists, pathologists, radiologists, and oncology pharmacists. The regional focus includes Northern California and the Northwestern United States.
Upon completion of this conference, participants will be able to:
the most clinically relevant updates from WCLC, including data on early detection, staging, and novel therapeutic strategies for thoracic malignancies.
results from recent clinical trials and assess their implications for local and regional treatment practices.
evidence-based approaches into multidisciplinary care plans, including surgical, radiation, and medical oncology interventions.
current guidelines and innovations in low-dose CT screening and biomarker-driven diagnostics to improve early detection and personalized treatment selection
effectively across specialties to align treatment decisions with best practices and patient-centered outcomes.
increased confidence in selecting and sequencing therapies such as chemotherapy, targeted therapy, and immunotherapy based on the latest clinical evidence.